About this Research Topic
This Research Topic focuses on androgen-dependent diseases and their treatment. Although pharmaceutical companies have made efforts to develop proper therapies to treat diseases such as metastatic prostate cancer, the reality is that there is currently no side-effect-free therapy that improves this and other androgen-dependent conditions.
GLOBOCAN estimates (2020) indicate that prostate cancer is the second leading cause of cancer and the leading cause of cancer death in men worldwide. Currently, therapies to control prostate cancer are based on surgical or chemical castration; both are traumatic for the patient, who must give up his sexual life. Enzyme inhibitors and antiandrogens represent a therapeutic improvement for this disease. However, it is necessary to review the advances made so far on the subject to provide patients with progress in their therapies.
Benign prostatic hyperplasia is another illness that continues to concern physicians. Therapies with inhibitors of 5α-reductase as dutasteride could be unattainable for poor people. Benign prostatic hyperplasia is a common androgen-dependent disease in around 50% of older men. This affliction can also improve shaving the prostate inside, but it is a very feared surgery for men.
Polycystic ovary syndrome is an androgen-dependent disease that increases testosterone and insulin levels in women's blood, causing awful symptoms. This disease can lead to sterility and cause a lot of stress in women who suffer from it.
In addition, this Research Topic ambitiously aims to motivate pharmaceutical companies to link up with research groups working in this branch to advance together in this race against the disease.
This research aims to contribute new knowledge for improving therapies for androgen-dependent diseases.
The contributors may address the current knowledge of the points in the below list:
1. Steroidogenesis in androgen-dependent tissues.
2. Androgen-dependent diseases.
3. Enzymes involved in steroidogenesis, as pharmacological targets.
4. The androgen receptor and its role in androgen-dependent diseases.
5. Pharmacological targets to treat prostate cancer metastases.
6. Current therapies to treat androgen-dependent diseases.
7. Development of new drugs to treat androgen-dependent diseases.
GLOBOCAN estimates (2020) indicate that prostate cancer is the second leading cause of cancer and the leading cause of cancer death in men worldwide. Currently, therapies to control prostate cancer are based on surgical or chemical castration; both are traumatic for the patient, who must give up his sexual life. Enzyme inhibitors and antiandrogens represent a therapeutic improvement for this disease. However, it is necessary to review the advances made so far on the subject to provide patients with progress in their therapies.
Benign prostatic hyperplasia is another illness that continues to concern physicians. Therapies with inhibitors of 5α-reductase as dutasteride could be unattainable for poor people. Benign prostatic hyperplasia is a common androgen-dependent disease in around 50% of older men. This affliction can also improve shaving the prostate inside, but it is a very feared surgery for men.
Polycystic ovary syndrome is an androgen-dependent disease that increases testosterone and insulin levels in women's blood, causing awful symptoms. This disease can lead to sterility and cause a lot of stress in women who suffer from it.
In addition, this Research Topic ambitiously aims to motivate pharmaceutical companies to link up with research groups working in this branch to advance together in this race against the disease.
This research aims to contribute new knowledge for improving therapies for androgen-dependent diseases.
The contributors may address the current knowledge of the points in the below list:
1. Steroidogenesis in androgen-dependent tissues.
2. Androgen-dependent diseases.
3. Enzymes involved in steroidogenesis, as pharmacological targets.
4. The androgen receptor and its role in androgen-dependent diseases.
5. Pharmacological targets to treat prostate cancer metastases.
6. Current therapies to treat androgen-dependent diseases.
7. Development of new drugs to treat androgen-dependent diseases.
Keywords: Androgens, prostate cancer, acne, steroidogenesis, androgen receptor, 5α-reductase
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
